are ac acute r rap apid id on onset an anti dep epres
play

Are ac acute r rap apid id on onset an anti-dep epres essant - PowerPoint PPT Presentation

Are ac acute r rap apid id on onset an anti-dep epres essant r results v valid, o or j just a a consequence o e of f functi tional unblinding? g? Stephen Brannan Mark Opler Torsten Madsen Disclosures- S Brannan Current


  1. Are ac acute r rap apid id on onset an anti-dep epres essant r results v valid, o or j just a a consequence o e of f functi tional unblinding? g? Stephen Brannan Mark Opler Torsten Madsen

  2. Disclosures- S Brannan • Current Employee at Karuna Pharmaceuticals • Former employee at: • Forum • Takeda • Novartis • Cyberonics • Eli Lilly

  3. RAAD Development • In 2006, labs at NIMH explored ketamine infusions and their findings spawned both excitement and a number of new “targets” • Several companies and “compounds” are currently making their way through the system • These “compounds” behave differently from traditional antidepressants and thus may not ideally fit the “traditional” tools and systems for development

  4. Unresolved Problems in Neuroscience Drug Development: Are Patients with Suicidal Ideation or Behavior Acceptable for Inclusion in Clinical Trials? Are Acute Rapid Onset Anti-depressants Results Valid or Just a Consequence of Functional Unblinding?

  5. Summary o of Points Discussed • Mark Opler • Esketamine has shown a rapid benefit in depressive Sx (IV & nasal) • “Unblinding” Dissociative sx are not driving the benefit because: • Dissociative Sx only explain a small part of the variance • Glyx-13 (w/o dissociative Sx) also showed rapid benefit in depressive Sx • Use of blinded independent raters correlates quite well with site ratings • Torsten Madsen • RAAD like Rx has been pursued before with sleep deprivation, ECT, etc • The correct durations and outcome measures still have not yet been developed and are unlikely to be simply the standard antidepressant outcomes • Unblinding is always an important element in trials and frequently appears to favor a treatment • Thus extra efforts are required for ensuring results are valid

  6. Issues r s req equiri ring F Further Di Disc scussi ssion • Were the study designs and outcome measures “fit for purpose” for these NCEs that are different from more traditional development targets? • How important is unblinding • What measures need to be taken to mitigate problems • What else have these discussants missed that you believe is important??

Download Presentation
Download Policy: The content available on the website is offered to you 'AS IS' for your personal information and use only. It cannot be commercialized, licensed, or distributed on other websites without prior consent from the author. To download a presentation, simply click this link. If you encounter any difficulties during the download process, it's possible that the publisher has removed the file from their server.

Recommend


More recommend